InMed Pharmaceuticals Inc. (OTCMKTS:IMLFF – Get Free Report)’s stock price traded down 5.2% during mid-day trading on Tuesday . The stock traded as low as $0.35 and last traded at $0.36. 60,538 shares were traded during trading, an increase of 432% from the average session volume of 11,369 shares. The stock had previously closed at $0.38.
InMed Pharmaceuticals Stock Performance
The firm’s 50 day simple moving average is $0.36 and its 200-day simple moving average is $0.47.
InMed Pharmaceuticals Company Profile
InMed Pharmaceuticals Inc, a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of orofacial pain.
Featured Articles
- Five stocks we like better than InMed Pharmaceuticals
- Manufacturing Stocks Investing
- 3 Value Stocks Too Small For Buffett’s Portfolio
- Bank Stocks – Best Bank Stocks to Invest In
- Foot Locker Builds Up Another Head of Steam; Gains Imminent
- How to Invest in Insurance Companies: A Guide
- Disney Stock Catches 3 Upgrades In a Single Week
Receive News & Ratings for InMed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for InMed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
